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ABSTRACT 
Small interfering RNA (siRNA) has recently illustrated therapeutic potential for 
malignant disorders. However, the clinical application of siRNA-based therapeutics is 
significantly retarded by the paucity of successful delivery systems. Recently, 
multifunctional gold nanoparticles (AuNPs) as non-viral delivery carriers have shown 
promise for transporting chemotherapeutics, proteins/peptides, and genes. In this 
study, AuNPs capped with polyethylenimine (PEI) and PEGylated anisamide (a 
ligand known to target the sigma receptor) have been developed to produce a range of 
positively charged anisamide-targeted PEGylated AuNPs (namely Au-PEI-PEG-AA). 
The Au110-PEI-PEG5000-AA construct effectively complexed siRNA via electrostatic 
interaction, and the resultant complex (Au110-PEI-PEG5000-AA.siRNA) illustrated 
favourable physicochemical characteristics, including particle size, surface charge, 
and stability. In vitro, Au110-PEI-PEG5000-AA selective bound to human prostate 
cancer PC-3 cells, inducing efficient endosomal escape of siRNA, and effective 
downregulation of the RelA gene. In vivo, prolonged systemic exposure of siRNA was 
achieved by Au110-PEI-PEG5000-AA resulting in significant tumour growth 
suppression in a PC3 xenograft mouse model without an increase in toxicity. In 
addition, a combination of siRNA-mediated NF-κB knockdown using 
Au110-PEI-PEG5000-AA with Paclitaxel produced a synergistic therapeutic response,  









Prostate cancer is a leading cause of cancer-related fatalities for male population, in 
2018 a total of 29,430 new cases and 164,690 deaths from this malignant disorder are 
forecasted to occur in the United States [1]. Recent advances in understanding the 
molecular pathology underlying prostate carcinogenesis have provided significant 
opportunities for the application of gene-based therapeutic strategies [2]. Small 
interfering RNA (siRNA), which results in sequence-specific post-transcriptional 
gene silencing in mammalian cell lines, has shown impressive anti-cancer potential 
[3]. However, the paucity of successful delivery systems dramatically retards the 
clinical translation of siRNA-based therapeutics for cancer [4].  
Recently, the development of novel organic and inorganic materials has 
revolutionised the field of siRNA delivery for treatment of solid tumours [5] [6] [7] 
and haematopoietic malignancies [8] [9]. As a result, a variety of non-viral siRNA 
delivery nanoparticle (NP) formulations have been developed for prostate cancer 
therapy [10]. Despite the promise, significant challenges such as inefficient siRNA 
encapsulation or complexation, in vitro and in vivo NP instability, non-specific cell 
binding, poor endosomal or lysosomal escape, and low gene knockdown efficacy, 
remain to be overcome before siRNA-based therapeutics can be widely accepted for 
use in patients with prostate cancer.   
Among the diverse range of nanoparticulate delivery carriers, gold NPs (AuNPs) have 
been utilised to develop siRNA nanomedicines mainly due to favourable 
physicochemical properties [11]. Previously, spherical positively charged AuNPs 
were synthesised using surfactant-free methods in the present of L-cysteine methyl 
ester hydrochloride [HSCH2CH(NH2)COOCH3·HCl] [12] with poly (ethylenimine) 
(PEI) [13] as the capping agents. Although these positively charged AuNPs 
(Au-L-cysteine and Au-PEI) demonstrated effective gene silencing in vitro, activity 
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was curtailed due to to non-specific binding to serum proteins [12] [13]. When 
Au-L-cysteine was further modified with polyethylene glycol (PEG), stability in 
serum-containing medium was improved [14]; however, these PEGylated AuNPs 
displayed poor cellular uptake due to the “PEG dilemma” phenomenon [15]. 
Bi-functional PEG moieties on AuNPs have therefore been exploited to facilitate 
conjugation of targeting ligands, resulting in cell-specific internalisation [16].  
Informed by previous studies, a range of novel spherical AuNPs were developed in 
this study for targeted delivery of siRNA in the treatment of prostate cancer. The 
spherical Au core was initially coated with PEI to achieve a cationic surface (Au-PEI) 
capable of complexing siRNA. To enhance stability in physiological environments 
and mediate selective uptake in prostate cancer cells, Au-PEI was further modified by 
PEGylated anisamide (AA, a ligand known to target the sigma receptor overexpressed 
on the prostate cancer cell membrane [17] [18]) to generate a PEGylated Au-AA 
targeted construct, Au-PEI-PEG-AA. The resultant complex of Au-PEI-PEG-AA with 
siRNA against RelA gene (a gene product from the NF-κB transcription factor 
complex) was investigated alone and in combination with paclitaxel for therapeutic 
efficacy in a prostate carcinoma xenograft mouse model. 
 
2. Materials and methods 
2.1. Materials 
PC-3 (human prostate cancer cell line) and CT26 (mouse colon cancer cell line) were 
purchased from the American Type Culture Collection (ATCC, USA). Negative 
control siRNA (siNeg) (sense sequence 5’-UUC UCC GAA CGU GUC ACG U-3’, 
no modification), FAM-labelled siRNA (siFAM) [sense sequence 5’-UUC UCC GAA 
CGU GUC ACG U-3’, modified by carboxyfluorescein (FAM) on 5’ of sense 
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sequence], and RelA siRNA (siRelA) (sense sequence 5’-CCA UCA ACU AUG 
AUG AGU U-3’) were purchased from GenePharma Co., Ltd., Shanghai, China. 
These HPLC-purified siRNAs were prepared in RNase-free water following 
manufacturer’s recommendations.  
Tetrachloroauric acid trihydrate (HAuCl4.3H2O), L-ascorbic acid (C6H8O6), 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC.HCl), 
N-hydroxysuccinimide (NHS), N,N-Diisopropylethylamine (DIPEA) purified by 
re-distillation, branched PEI solutions (Mw = 2 kDa, 50 % w/v), p-Anisic acid 
(99.5%), dry dichloromethane (DCM), dry pentane, magnesium sulfate (MgSO4), and 
thiol PEG Amine (HS-PEG7500-NH2 and HS-PEG3500-NH2) were purchased from 
Sigma-Aldrich. In addition, HS-PEG5000-NH2 was obtained from PEG Creative Work. 
All chemicals were used as received without any further purification. 
2.2. Synthesis of AuNPs 
Purified H2O (resistivity ≈ 18.2 MΩ cm) was used as a solvent for AuNP synthesis. 
Glassware was cleaned with aqua regia (3 parts of concentrated HCl and 1 part of 
concentrated HNO3), rinsed with distilled water, ethanol and acetone, and dried 
overnight before use. 
2.2.1. Optical spectra  
The optical absorption spectra were obtained using the Evolution 60 UV-Visible 
spectrophotometer with a Xenon Flash Lamp (300-1100 nm range, 0.5 nm resolution) 
(Thermo Fisher Scientific). 
2.2.2. Scanning electron microscopy (SEM) 
AuNP samples were deposited onto a Silicon wafer and air-dried prior to analysis 
using a FEI 630 NanoSEM equipped with an Oxford INCA energy dispersive X-ray 
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(EDX) detector operated at 5 kV. 
2.2.3. Nuclear magnetic resonance (NMR) 
NMR was recorded in deuterated chloroform (CDCl3) using a Bruker NMR (400 or 
300 MHz) at ambient temperature. 
2.2.4. Dynamic light scattering (DLS) 
Particle size and zeta potential were measured in deionised water (0.2 μm 
membrane-filtered) using the Malvern Nano-ZS (Malvern Instruments, UK) at 25 °C 
with the default non-invasive back scattering (NIBS) technique at a detection angle of 
173°.  
2.2.5. Synthesis of Au-PEI  
Au-PEI with ~ 25 nm of diameter (Au25-PEI): 2.6 mL of freshly prepared 
HAuCl4.3H2O aqueous solution (19.8 mM) was added into 47.5 mL of water at 30 °C, 
followed by the addition of 1.55 mL of PEI aqueous solution (5 mM). When PEI was 
added into the solution, the colour changed from light to deep yellow indicating the 
interaction between the amino groups of PEI and the Au metal ions, similar to that 
previously observed [13], 0.83 mL of aqueous L-ascorbic acid (250 mM) was added 
into the solution with stirring at room temperature (RT) until the colour changed to 
deep red.  
Au-PEI with ~ 60 nm of diameter (Au60-PEI): 50 mL of freshly prepared HAuCl4.3H2O 
aqueous solution (0.25 mM) were added into 0.1 mL of PEI aqueous solution (5 mM) 
at RT, 0.775 mL of L-ascorbic acid (100 mM) were further added into the solution and 
stirred at RT for 41 h.  
Au-PEI with ~ 95 nm of diameter (Au95-PEI): 50 mL of freshly prepared HAuCl4.3H2O 
aqueous solution (0.25 mM) were added into 0.025 mL of PEI aqueous solution (5 
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mM) at RT. Subsequently, 0.775 mL of L-ascorbic acid (100 mM) were added into the 
solution and stirred at RT for 20 h.  
Au-PEI with ~ 110 nm of diameter (Au110-PEI): 50 mL of freshly prepared 
HAuCl4.3H2O aqueous solution (1 mM) were added into 0.3 mL of PEI aqueous 
solution (5 mM) at RT. Subsequently, 0.775 mL of L-ascorbic acid (100 mM) was 
added into the solution and stirred at RT for 3 h.  
2.2.6. Synthesis of NHS-activated anisic acid 
NHS-activated anisic acid was produced as previously described [13]. Briefly, 
EDC.HCl (1.5 eq, 1.9 g, 9.9 mM) was added to the p-anisic acid solution (1 g, 6.572 
mM) in dry DCM (250 ml) under Argon, followed by the addition of NHS (1.45 eq, 
1.1 g, 9.56 mM). The reaction mixture was stirred for ~ 42 h under Argon at RT. The 
organic phase was washed twice with water followed by a wash with brine, dried over 
MgSO4, filtered on Whatman filter paper, and evaporated. The activated ester thus 
obtained was left to stir in 30 mL of dry pentane for ~ 48 h, filtered, dried under 
vacuum, and used without further purification. The yield of the anisic-NHS ester 
(AA-NHS) was approximately 90%. The product was analysed using NMR 
spectroscopy [(400 MHz, CDCl3): δ ppm 8.08-8.11 (d, 2H, ArH-CO-), 6.97-6.99 (d, 
2H, ArH-OCH3), 3.89 (s, 3H, OCH3), 2.91 (s, 4H CH2-CH2 in NHS ring)] [13]. 
2.2.7. Synthesis of PEGylated anisamide (PEG-AA) 
SH-PEG3500-AA: 140 mg of SH-PEG3500-NH2 (0.04 mM) were dried under vacuum 
for 10 min at RT, using? a flow of nitrogen (N2), and dried under vacuum for 5 min at 
RT. The SH-PEG3500-NH2 powder was then dissolved in 4 mL DCM under N2 and 4 
mL of AA-NHS (20 mg, 0.08 mM) was added and stirred in dry DCM at 0 °C. 
Subsequently, 120 µL of DIPEA (0.705 mM) in dry DCM was added and incubated 
with stirring under N2 at RT for 48 h. The resultant SH-PEG3500-AA was precipitated 
at 0 °C using 100 mL cold diethyl ether/ethanol solution (v/v = 99/1). The 
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SH-PEG3500-AA was collected at 0 °C by centrifugation at 11,000 rpm and dried 
overnight under the vacuum. The SH-PEG3500-AA (~ 90% yield) was characterised by 
NMR in CDCl3: δ ppm 7.78-7.80 (d, 2H, ArH-CO-), 6.91-6.93 (d, 2H, 
ArH-OMethyl), 3.85 (s, Ar-OCH3), 3.65 (O-CH2-CH2 of PEG), 2.9 (CH2-C=O). The 
degree of anisamide attachment was ~ 95% as calculated from the peak integration 
ratio of phenyl proton at δ 7.78 to methylene protons at δ 3.65. 
SH-PEG5000-AA: 100 mg of SH-PEG5000-NH2 (0.02 mM) were dried under the 
vacuum for 10 min at RT, using N2, and dried under the vacuum for 5 min at RT. The 
SH-PEG5000-NH2 powder were then dissolved in 4 mL of DCM under N2 and 2 mL of 
AA-NHS (8.5 mg, 0.034 mM) in dry DCM was added and stirred at 0 °C. 
Subsequently, 50 µL of DIPEA (0.615 mM) in dry DCM was added and stirred under 
N2 at RT for 48 h. The resultant SH-PEG5000-AA was precipitated at 0 °C using 100 
mL cold diethyl ether/ethanol solution (v/v = 99/1). The SH-PEG5000-AA was 
collected at 0 °C by centrifugation at 11,000 rpm and dried overnight under the 
vacuum. The SH-PEG5000-AA (~ 90% yield) was characterised by NMR in CDCl3: δ 
ppm 7.79-7.81 (d, 2H, ArH-CO-), 6.90-6.92 (d, 2H, ArH-OMethyl), 3.85 (s, 
Ar-OCH3), 3.65 (O-CH2-CH2 of PEG), 2.9 (CH2-C=O). The degree of anisamide 
attachment was ~ 100% as calculated from the peak integration ratio of phenyl proton 
at δ 7.78 to methylene protons at δ 3.65. 
SH-PEG7500-AA: 150 mg of SH-PEG7500-NH2 (0.02 mM) were dried under the 
vacuum for 10 min at RT, using N2, and dried under the vacuum for 5 min at RT. The 
SH-PEG7500-NH2 powder were then dissolved in 4 mL of DCM under the N2 and 2 
mL of AA-NHS (10 mg, 0.04 mM) in dry DCM was added and stirred at 0 °C. 
Subsequently, 60 µL of DIPEA (0.705 mM) in dry DCM was added and stirred at RT 
for 48 h. The resultant SH-PEG7500-AA was precipitated at 0 °C using 100 mL cold 
diethyl ether/ethanol solution (v/v = 99/1). The SH-PEG7500-AA was collected at 0 °C 
by centrifugation at 11,000 rpm for 5 min and dried overnight under the vacuum. The 
SH-PEG7500-AA (~ 90% yield) was characterised by NMR in CDCl3: δ ppm 7.78-7.80 
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(d, 2H, ArH-CO-), 6.91-6.93 (d, 2H, ArH-OMethyl), 3.85 (s, Ar-OCH3), 3.65 
(O-CH2-CH2 of PEG), 2.9 (CH2-C=O). The degree of anisamide attachment was ~ 
95% as calculated from the peak integration ratio of phenyl proton at δ 7.78 to 
methylene protons at δ 3.65. 
2.2.8. PEGylation of Au-PEI (Au-PEI-PEG and Au-PEI-PEG-AA) 
The Au-PEI was PEGylated by adding SH-PEG-NH2 (100 μM) or SH-PEG-AA (100 
μM), in which the final concentrations were fixed approximately at a molar ratio of 
1:250 for SH-PEG-NH2/SH-PEG-AA and HAuCl4. This reaction was continued with 
stirring for ~ 6 to 16 h at RT. The resultant Au-PEI-PEG and Au-PEI-PEG-AA were 
collected by centrifugation at 11,000 rpm for 5 min. As a result, ~ 60% of the initial 
SH-PEG-NH2 and SH-PEG-AA were conjugated?? onto the Au surface, this was 
confirmed using UV-vis spectroscopy (Fig. S4). In addition, the successful 
PEGylation was confirmed using DLS and SEM.  
2.3. Cytotoxicity 
PC-3 and CT26 cells were maintained in RPMI-1640 medium (CORNING) 
supplemented with 10% FBS and a Penicillin-Streptomycin Nystatin solution 
(Biological Industries). Five thousand PC-3 or CT26 cells were seeded per well in 
96-well culture plates one day before transfection. AuNPs ([c] = 1, 5, 10, 20, 50, 100, 
250, 500 and 1000 μg/mL) were added to the cells for 72 h under normal growth 
conditions. Following incubation, cells were incubated with 20 μL 
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) stock (5 
mg/mL in PBS) in 200 μL fresh growth medium for 4 h at 37 °C. ~ 100 to 200 μL 
DMSO was added to dissolve the purple formazan products. The results were read at 
570 nm using a microplate reader.  
2.4. Preparation and physicochemical characterisation of AuNP.siRNA complexes  
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Solutions of Au-PEI, Au-PEI-PEG, and Au-PEI-PEG-AA (1 μg/μL) were added to 
siRNA solutions at different weight ratios (WRs) of AuNPs to siRNA, followed by 2 
h sonication at 55-60 °C. The efficiency of AuNPs to complex siRNA was assessed 
using gel retardation assay [16]. Briefly, solutions of AuNPs and siRNA (0.2 μg 
siNeg) at various WRs were loaded onto 1% (w/v) agarose gels in Tris-Borate-EDTA 
(TBE) buffer containing the GelStain (Transgen Biotech, China). Electrophoresis was 
performed at 90 V for 20 min and the resultant gels were photographed under UV. 
Measurements of particle size and zeta potential of AuNP.siRNA complexes were 
performed as described in section 2.2.5. The concentration of siRNA was fixed at 1 
μg/mL. 
Complexes containing 0.2 μg siNeg at WR40 were incubated for 1, 2, 4 and 8 h in 
50% (v/v) fetal bovine serum (FBS; Gibco) at 37 °C. After incubation, samples were 
heated for 5 min at 80 °C for serum inactivation. Samples were then treated with 
excess heparin (1000 IU/mL) at RT for 1 h to release siRNA from AuNPs. Samples 
were loaded onto 1.5% (w/v) agarose gels containing the GelStain. Electrophoresis 
was performed at 90 V for 20 min and the resultant gels were photographed under 
UV. 
In addition, complexes (WR40) were incubated in 50% (v/v) FBS at 37 °C for 24 h, 
and the particle sizes were measured using Malvern Nano-ZS as described in section 
2.2.5. FBS alone and complexes incubated in deionised water at 37 °C for 24 h were 
used as controls. The concentration of siRNA was fixed at 1 μg/mL.   
2.5. Cellular uptake  
PC-3 and CT26 cells were respectively seeded at 1 x 105 cells per well in 24-well 
culture plates one day before transfection. Cells were treated with AuNPs complexes 
(WR40) containing 50 nM siFAM and incubated for 8 h under normal growth 
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conditions. Following incubation, cells were washed twice with pre-warmed PBS and 
trypsinised. After 1000 rpm centrifugation for 5 min, the supernatant was discarded 
and cells were re-suspended in 1000 μL ice-cold PBS. 10,000 cells were measured for 
each sample according to the Becton Dickinson FACS-calibur manual.    
2.6. Intracellular trafficking 
PC-3 cells (1 x 105 cells per well) were seeded in 6-well culture plates with glass 
bottoms (JET BIOFIL®, China) for 24 h. Cells were treated with Au-PEI-PEG-AA 
complexes (WR40) containing 50 nM siFAM and incubated for 4 h under the normal 
growth conditions. Following this, cells were incubated in LysoTracker® Deep Red 
(75 nM; Invitrogen) at 37 °C for 30 min. Fresh growth medium was added to the cells 
prior to confocal microscopic analysis using an Olympus FV 1000 microscope.  
2.7. Gene knockdown 
PC-3 cells (1 x 105 cells per well) were seeded in 24-well culture plates. Following 24 
h incubation, cells were transfected by the Au-PEI-PEG-AA formulation (WR40) 
containing 100 nM siRelA for 24 h. After this, total RNA was isolated from cells 
using TransZol UP (Transgen Biotech, China). First-strand cDNA was generated from 
total RNA samples using TransScript® All-in-One First-Strand cDNA Synthesis 
SuperMix for qPCR (Transgen Biotech, China). Gene expression was assessed by 
real-time quantitative PCR (qPCR) using TransStart® Top Green qPCR SuperMix 
(Transgen Biotech, China). Assays were carried out using primers for RelA (forward: 
5’-GCC TCA TCC ACA TGA ACT TGT GGG-3’; reverse: 5’-ACC ATG GTC TGG 
GCA AGG ACT GGG -3’) and GAPDH (forward: 5’-ACC ACA GTC CAT GCC 
ATC AC-3’; reverse: 5’-TCC ACC ACC CCC TGT TGC TGT A-3’). Amplification 
was carried out under 40 cycles of denaturation at 94 °C (5 s) and annealing at 60 °C 
(30 s) (StepOnePlusTM Real-Time PCR System, Applied BiosystemsTM). The 
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quantitative level of each RelA mRNA was measured as a fluorescent signal corrected 
according to the signal for GAPDH mRNA. 
In addition, PC-3 cells (1 x 105 cells per well) were seeded in 24-well culture plates. 
Following 24 h incubation, cells were transfected by Au-PEI-PEG-AA formulation 
(WR40) containing 100 nM siRelA for 48 h. Subsequently, cells were lysed using 
RIPA buffer [50 mM Trish (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 1% SDS, sodium orthovanadate, sodium fluoride, EDTA, and 
leupeptin], and protein concentrations were quantified using the Easy II BCA Protein 
Quantitative Kit (GenStar, China). ~ 30-50 μg of proteins per sample were loaded 
onto an SDS-PAGE and electrophoresed at 80 V for 0.5 h and subsequently at 120 V 
for 1.5 h. Proteins were then transferred to a PVDF membrane (Immobilon-P 
Transfer Membrane; Millipore) at 200 mA for 1.5 h. Membranes were incubated with 
appropriate antibodies [RelA (#1574i53) and β-actin (#8427f55), purchased from 
Affinity, USA] at RT for 12 h. Antibody reactive bands were detected using 
MicroChemi (DNR Bio-Imaging Systems Ltd., Israel). Densitometry analysis of 
bands was performed using ImageJ, and all results were normalised to the β-actin 
control.  
2.8. In vitro anti-cancer effects 
PC-3 cells (100,000 per well) were seeded in 24-well culture plates for one day. 
Au-PEI-PEG-AA complexes (WR40) containing 100 nM siRelA were applied to the 
cells for 24 h. Cells were subsequently incubated with Annexin V-FITC and 
propidium iodide (PI) supplied from TransDetect® Annexin V-FITC/PI Cell 
Apoptosis Detection Kit (Transgen Biotech, China). The apoptotic cells were 
analysed using flow cytometry (Becton Dickinson FACS-calibur).        
PC-3 cells (5,000 per well) were seeded in 96-well culture plates. After 24 h, 
Au-PEI-PEG-AA complexes (WR40) containing 100 nM siRelA were added to cells 
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and incubated for 48 and 72 h. Following incubation, cells were treated with the 
TransDetect® Cell Counting Kit (CCK) (Transgen Biotech, China) and incubated for 
2 h before measuring the absorbance at 450 nm.  
In addition, PC-3 cells (5,000 per well) were seeded in 96-well culture plates. After 
24 h, Au-PEI-PEG-AA complexes (WR40) containing 100 nM siRelA were added to 
cells and incubated for 4 h. After this, cells were further treated with Paclitaxel (PTX, 
purchased from Hainan Choitec Pharmaceuticals Co., Ltd.; [c] = 50, 100 and 200 nM) 
for 20 h. Following incubation, cells were treated with the TransDetect® Cell 
Counting Kit (CCK) solution (Transgen Biotech, China) and incubated for 2 h before 
measuring the absorbance at 450 nm.  
2.9. Animal experiments 
The animal ethics committee of Jilin University approved all experiments. All mice 
were maintained in a pathogen free animal facility for at least 2 weeks before the 
experiments.  
2.10. In vivo toxic studies  
Male BALB/C mice (6-8 weeks) were purchased from Changchun Institute of 
Biological Products, China. Animals (n = 4 per group) were intravenously injected 
with the siNeg (~ 1 mg/kg) complexed with Au-PEI-PEG or Au-PEI-PEG-AA 
(WR40), 100 μL of saline (negative control) and 100 μg of poly 
polyinosinic:polycytidylic acid [poly (I:C)] (positive control). Blood samples were 
collected at 2 h post injection. Serum IFN-α was measured by the IFN alpha Mouse 
ELISA Kit (Invitrogen).  
In addition, mice (n = 4 per group) were intravenously injected with Au-PEI-PEG-AA 
formulations (WR40) containing siRelA (~ 1 mg/kg). After 4 h, animals were treated 
with intraperitoneal injection of PTX (~ 10 mg/kg). The body weight of mice was 
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recorded regularly. On the endpoint, major tissues (the heart, liver, spleen, lung and 
kidney) were collected and analysed using the haematoxylin and eosin (H & E) 
staining assay. In addition, blood samples were collected and analysed using a 
haemacytometer, in order to determine the haematological toxicity [19].   
2.11. Pharmacokinetics 
Male BALB/C mice (~ 20-22 g) (n = 4 per group) were intravenously injected with 
siFAM either alone (~ 1 mg/kg) or complexed with Au-PEI-PEG or Au-PEI-PEG-AA 
(WR40). Blood samples (~ 30 μL) were collected at 1, 3, 5, 10, 15, 30 and 60 min. 
The extraction and quantification of siFAM were carried out as described in [20]. The 
extraction efficiency of siFAM from Au-PEI-PEG and Au-PEI-PEG-AA was 94% 
and 96% respectively. The concentration of siFAM in plasma obtained from standard 
curves was corrected using these determined extraction efficiencies. Pharmacokinetic 
parameters were calculated using DAS 2.0.  
2.12. Tissue distribution  
The xenograft model was established by subcutaneous injection of 5 x 106 PC-3 cells 
into the flank of male BALB/c nude mice (5-6 weeks, purchased from Beijing Vital 
River Laboratory Animal Technology Co., Ltd.). Tumour growth was recorded 
regularly, and the volume was calculated using a formula a2b(π/6), where a is the 
minor diameter of the tumour and b is the major diameter perpendicular to diameter a. 
When the volume reached ~ 250 mm3, siFAM either alone (~ 1 mg/kg) or formulated 
with Au-PEI-PEG or Au-PEI-PEG-AA was intravenously injected into tumour 
bearing mice (n = 4 per group). Two hours post treatment, mice were sacrificed, and 
the organs (heart, liver, spleen, lung and kidneys) and tumours were collected. As 
described in [21], the liver was homogenised in 1mL lysis buffer, and other tissues 
were homogenised in 300 μL lysis buffer. The homogenised samples were incubated 
at 65 °C for 10 min. siFAM in the supernatant was extracted and measured as 
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described in section 2.11. The dose of siRNA accumulated in tissues was quantified 
from a strand curve obtained by spiking known amounts of siFAM alone or siFAM 
complexed with AuNPs in tissues from untreated mice [21].  
2.13. In vivo anti-tumour study 
When the tumour volume reached ~ 150 mm3, siRelA (~ 1 mg/kg) formulated with 
Au-PEI-PEG-AA was intravenously injected into animals (n = 4 per group) at Day 1, 
3 and 5. Four hours post-injection, PTX was intravenously injected at a dose of ~ 10 
mg/kg into the tumour bearing mice. Tumour growth and body weight were recorded 
regularly, and the tumour volume was calculated as described above. Treatments of 
saline, PTX alone and siNeg (~ 1 mg/kg) formulated with Au-PEI-PEG-AA were 
used as controls.  
2.14. Statistical analysis 
Data were calculated as the mean ± standard deviation (SD). An unpaired Student’s 
t-test (two-tailed) was used to test the significance of differences between two mean 
values. A one-way ANOVA (Bonferroni’s Post-Hoc test) was used to test the 
significance of differences in three or more groups. In addition, a two-way ANOVA 
(Bonferroni’s Post-Hoc test) was used to test the significance of differences in 
measurements of body weight, pharmacokinetics, and tumour growth. In all 
experiments, p < 0.05 was considered statistically significant. 
 
3. Results and discussion 
3.1. Synthesis and physicochemical characterisation of Au-PEI and Au-PEI-PEG-AA 
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Due to the ease of synthesis and biocompatibility gold nanoparticles (AuNPs) have 
been widely studied to formulate siRNA nanomedicines [11]. In this study, spherical 
AuNPs were used as a scaffold to produce positively charged anisamide-targeted 
PEGylated NPs for delivery of siRNA into prostate cancer. As previously reported 
[13], AuNPs were initially modified with branched PEI (Mw = 2 kDa) to achieve 
positively charged Au-PEI. It has been reported that PEI with high Mw (e.g. > 10 kDa) 
can generate higher transfection efficiency relative to low Mw PEI (e.g. 2 kDa) [22]. 
However, low Mw PEI is less toxic and more biocompatibile compared to high Mw 
PEI [23]. Consequently, PEI 2 kDa was to chosen to bind siRNA to the AuNPs and to 
facilitate intracellular release (see section 3.4.2). 
Au-PEI NPs with a range of particle sizes namely; Au25-PEI, Au60-PEI, Au95-PEI and 
Au110-PEI, were synthesised by the conjugation of PEI onto the surface of AuNPs. 
Conjugation was confirmed by UV-vis spectroscopy indicating that a red shift of ~ 50 
nm accompanied by peak broadening which was clearly observed when the particle 
size increased from ~ 25 to 100 nm (Fig. 1a). The Au110-PEI presented a spherical 
shape with a diameter of ~ 110 nm (Fig. 1b). The Au25-PEI, Au60-PEI and Au95-PEI 
demonstrated similar morphology with diameters of ~ 25, 60 and 95 nm, respectively 
(Fig. S1). In contrast to SEM results, the particle size of Au-PEI obtained from the 
DLS was slightly larger (Fig. 1c and Table S1), indicating that the AuNPs were 
successfully coated with PEI. In addition, the positive surface charge of the Au-PEI 
gradually decreased as the particle size of the AuNPs increased (Fig. 1d and Table 
S1).  
The anisic acid was activated by reacting with NHS to form an anisic-NHS ester 
(AA-NHS), which was confirmed using NMR (Fig. S2). The AA-NHS reacted with 
the amino group (-NH2) of SH-PEG-NH2 to form a stable amide linkage, producing 
SH-PEG-AA (Fig. S3). The Au-PEI was subsequently chemically modified with 
SH-PEG-AA to form cationic anisamide-targeted PEGylated AuNPs 
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(Au-PEI-PEG-AA). Results in Fig. 2a indicate that the particle size of 
Au-PEI-PEG-AA with the same core size (e.g. Au110-PEI) was clearly increased with 
the PEG Mw (Table. S1). In contrast, the zeta potential of Au-PEI-PEG-AA with the 
same core size (e.g. Au110-PEI) was gradually decreased with increasing the PEG Mw 
(Fig. 2b and Table S1). In addition, a thin ‘halo-like’ layer was clearly observed on 
the surface of Au-PEI-PEG-AA (Fig. 2c), most likely due to the attachment of PEG 
chains. In summary, these results imply or show?? that the PEGylated anisamide was 
successfully conjugated to the surface of Au-PEI. 
3.2. Cytotoxicity of Au-PEI-PEG and Au-PEI-PEG-AA 
It is well established that physicochemical characteristics (i.e. particle size, surface 
charge, particle shape and surface coating [24]) can significantly affect the toxicity of 
delivery NPs [11]. The in vitro toxicity of Au-PEI-PEG and Au-PEI-PEG-AA was 
assessed using human prostate cancer PC-3 cells (Table S2). Results show that the 
attachment of PEG with increasing Mw to AuNPs with the same core size (e.g. 
Au110-PEI) significantly enhanced cell viability; for example, IC50 values of 
Au110-PEI-PEG3500-AA, Au110-PEI-PEG5000-AA and Au110-PEI-PEG7500-AA in PC-3 
cells were approximately 390, 440 and 500 µg/mL respectively. In addition, the 
cytotoxicity of AuNPs with the same PEG length was significantly reduced when the 
particle size was increased; for instance, IC50 values of Au25-PEI-PEG5000-AA, 
Au60-PEI-PEG5000-AA, Au95-PEI-PEG5000-AA and Au110-PEI-PEG5000-AA in PC-3 
cells were approximately 100, 200, 330 and 440 µg/mL respectively. Similar IC50 
values were also recorded for AuNPs in CT26 cells (data not shown). 
Recently, NPs have been modified with multifunctional ligands that can 
simultaneously enable delivery to target tissues/cells [25] [26] [27] and release drugs 
via stimuli-responsive means either extracellularly and/or intracellularly [28] [29] 
[30], in order to achieve personalised and effective therapeutic regimens. However, 
potential toxicity may be caused by interaction with specific cell receptors, cell 
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membranes, or intracellular organelles [11]. The sigma receptor is known to be 
overexpressed on the cell membrane of various human (PC-3, DU-145 and LNCaP) 
and mouse (Tramp C1) prostate cancer cell lines [31] [32] [33]. It is interesting to 
note that anisamide-targeted AuNPs demonstrated slightly higher PC-3 cell death 
compared to non-targeted counterparts (Table S2). In contrast, no significant 
difference in cytotoxicity was found between Au-PEI-PEG and Au-PEI-PEG-AA in 
CT26 cells (a cell line where the sigma receptor is less well expressed [34]) (data not 
shown). Therefore, these results suggest that the cytotoxic profiles of 
Au-PEI-PEG-AA may be dependent on the density of sigma receptors in cell lines 
(see discussion in section 3.4). On the basis of the cytotoxicity results, the 
concentrations of Au-PEI-PEG and Au-PEI-PEG-AA used for the following in vitro 
experiments ensured > 90% of cell viability. 
3.3. Complexation of siRNA with Au-PEI-PEG and Au-PEI-PEG-AA 
The formation of AuNP and siRNA complexes via the electrostatic interaction 
between cationic PEI and anionic siRNA was assessed using gel a retardation assay 
(Fig. 3a, S5, S6 and S7). Results show that full binding of siRNA with 
Au110-PEI-PEG5000 and Au110-PEI-PEG5000-AA was achieved from WR40 of AuNPs 
and siRNA onwards (Fig. 4a). However, the AuNPs with smaller diameters did not 
bind siRNA as efficiently as the bigger counterparts (Fig. S6), most likely due to the 
fact that the bigger Au core, particularly with the spherical shape, may provide more 
binding space for small nucleic acids with a stiff rod-like structure (e.g. siRNA) (Fig. 
1??). In addition, it is interesting to note that AuNPs with shorter PEGylation (Mw = 
3500 kDa) achieved full complexation with siRNA at WR20 onwards, but full 
binding of siRNA was achieved only from WR40 onwards by AuNPs with longer 
PEGylation (Mw = 5000 and 7500 kDa) (Fig. S7). As the AuNPs are modified with 
the same grafting density (i.e. ~ 60%, Fig. S4), a possible explanation is that the PEG 
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with the higher Mw (proportional to the chain length) on the Au surface may fold 
back and overlap each other thus negatively affecting the siRNA binding efficiency.  
The ability of Au-PEI-PEG-AA to protect siRNA from serum nucleases was 
evaluated in 50% FBS-containing medium at 37 °C (Fig. 3b). Unlike the naked 
siRNA which degraded significantly after 1 h incubation (data not shown), the siRNA 
formulated with Au110-PEI-PEG5000-AA (WR40) was resistant to serum degradation 
upto 8 h. In addition, following incubation in 50% FBS-containing medium at 37 °C, 
the Au110-PEI-PEG3500-AA.siRNA formulation aggregated at WR40, in contrast the 
AuNP formulations (WR40) with longer PEG chains (Mw = 5000 and 7500 kDa) 
significantly inhibited the binding of serum proteins (Fig. 3c). Based on these 
physicochemical characteristics (Fig. 3, S5, S6 and S7), the 
Au110-PEI-PEG5000-AA.siRNA formulation (WR40) was used for all further in vitro 
and in vivo experiments. 
3.4. In vitro mechanistic studies using AuNP.siRNA complexes 
3.4.1. Cellular uptake  
Recently, a variety of delivery NPs modified with the anisamide or anisamide-derived 
targeting ligands have been developed to deliver nucleic acids in the treatment of 
cancer [35] [36] [37] [38] [39] [40]. Here, the selective cellular uptake of FAM 
labelled siRNA (siFAM) complexed with Au110-PEI-PEG5000 or 
Au110-PEI-PEG5000-AA (WR40, 50 nM siRNA) was investigated in both PC-3 (a 
sigma receptor overexpressing cell line [18]) and CT26 (a cell line where the sigma 
receptor is less well expressed [34]). As shown in Fig. 4a, Au110-PEI-PEG5000-AA 
significantly enhanced the uptake of siRNA into PC-3 cells (~ 45%) compared to the 
untargeted Au110-PEI-PEG5000 (~ 15%). In the case of CT26 cells cellular uptake by 
Au110-PEI-PEG5000-AA was significantly reduced (~ 20%) and was only slightly 
higher than that obtained by Au110-PEI-PEG5000 (~ 15%) (Fig. 4a). These results 
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indicate that the anisamide-targeted AuNP.siRNA construct has an increased binding 
affinity for PC-3 cells suggesting the cellular uptake is principally mediated via the 
sigma receptor. 
The sigma receptor consists of two main subclasses namely sigma-1 receptor (σ1R) 
and sigma-2 receptor (σ2R) [41]. The sigma receptor was earlier detected in the 
central nervous system of mammals [42] and recently, both sigma receptor subtypes 
have been found to overexpress in human cancer cell lines and patient tumour tissues 
[41]. NPs targeting σ1R have shown promise and recently, a number of studies have 
demonstrated the successful application of σ1R in drug delivery for cancer therapy 
[38] [39] [40]. In addition, due to overexpression of σ2R on the cell membrane of 
various human and mouse tumour cell lines [44] [45] [46], it also has potential as a 
targeting ligand for diagnostic imaging and therapy. Compounds targeting σ2R are 
currently under investigation for the diagnosis of breast cancer (clinical trial 
NCT02762110) and for the treatment of Alzheimer’s disease (clinical trial 
NCT02907567). A debate on the role of σ1R as the receptor for targeted drug 
delivery has been raised, however the tumour-targeting specificity of σ1R cannot be 
denied in the absence of more conclusive studies [43].  
Due to the lack of appropriate pharmacological inhibitors that selectively block the 
sigma receptors [43], it is difficult to determine whether single subtypes or both are 
associated with the receptor-mediated internalisation of Au-PEI-PEG-AA, this will be 
the focus of future work. 
3.4.2. Intracellular trafficking 
Following ligand-receptor mediated internalisation, NPs are normally trapped in 
endosomes where the pH becomes slightly acidic (~ 5 to 6). Subsequently, NPs are 
transported into lysosomes in which the pH drops further (~ 4.5) and various 
degradative enzymes may dissociate NP formulations and degrade siRNA. It has been 
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reported by Gilleron and colleagues that a lipid-based NP delivery system (LNP) 
released siRNA from endosomes into the cytoplasm at low efficiency (1-2%) [47]. In 
addition, Sahay et al. reported that ~ 70% of internalised siRNA formulated with 
LNPs underwent exocytosis from lysosomes [48]. These studies indicate that delivery 
nanocarriers must efficiently release siRNA from the endosomes or lysosomes, in 
order to successfully initiate the RNAi machinery in the cytoplasm.  
It has been reported that AuNPs with certain shapes (e.g. Au nanoshells and 
nanocages) can absorb the light in the near-infra red (NIR) to induce photothermal 
effects that can assist the endosomal escape of siRNA [49]. In addition, modification 
of AuNPs with functional groups (e.g. pH-sensitive and enzymes-responsive moieties) 
may also assist the endosomal release of siRNA [11]. For example, PEI is known to 
be efficiently in facilitating endosomal escape via the “proton sponge effect” whereby 
the acidic pH in endosomes protonates PEI causing an increase in osmotic pressure 
and subsequent membrane rupture [50].  
The intracellular trafficking of anisamide-targeted AuNPs was studied in PC-3 cells 
using FAM-labelled siRNA (Fig. 4b). After 4 h incubation with 
Au110-PEI-PEG5000-AA.siFAM (WR40, 50 nM siRNA), fluorescence (green) was 
detected inside the cells, mainly in the cytoplasm and without co-localisation with the 
lysosomal marker (red) (Fig. 4b). These results indicate that Au110-PEI-PEG5000-AA 
achieved efficient endosomal escape of sRNA within 4? h, most likely due to the 
PEI-mediated “proton sponge effect”, these results are similar to those previously 
reported for other PEI-modified AuNPs [13] [16].  
3.4.3. Gene knockdown 
The nuclear factor κ-B (NF-κB) is a substantially investigated transcription factor that 
has been implicated in cell proliferation, angiogenesis and metastasis of prostate 
carcinoma [2]. The NF-κB is a combination of five gene products (RelA, RelB, c-Rel, 
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NF-κB1 and NF-κB2) [51]. Here, the endogenous gene silencing of anti-RelA siRNA 
(100 nM) using Au-PEI-PEG-AA (WR40) was studied in PC-3 cells (Fig. 5). 
Following 24 h incubation, siRelA formulated with Au110-PEI-PEG5000-AA 
significantly (p < 0.01) reduced the RelA mRNA level relative to negative controls 
including naked siRelA, siRelA formulated with Au110-PEI-PEG5000, and siNeg 
formulated with Au110-PEI-PEG5000-AA (Fig. 5a). In addition, siRelA formulated with 
Au110-PEI-PEG5000-AA also significantly (p < 0.01) down-regulated RelA protein 
expression after 48 h incubation relative to the aforementioned negative controls (Fig. 
5b and S8). It is worth noting that siRelA formulated with Au110-PEI-PEG5000-AA 
resulted in significantly (p < 0.05) greater gene silencing compared to 
Lipofectamine 2000 (a commercially available lipid-based transfection reagent used 
as a positive control in this study) (Fig. 5 and S8), indicating the therapeutic potential 
of the Au110-PEI-PEG5000-AA construct as a nanoparticulate siRNA delivery system 
for prostate cancer. 
3.4.4. In vitro anti-cancer efficacy  
Following efficient NF-κB knockdown, the anisamide-targeted formulation (WR40, 
100 nM siRelA) induced significant levels of apoptosis in PC-3 cells (p < 0.01, 24 h 
incubation) compared to negative controls (Fig. 6a). Due to the apoptotic effects, 
Au110-PEI-PEG5000-AA.siRelA significantly slowed down the proliferation of PC-3 
cells (p < 0.01; ~ 40% and 60% reductions after 48 h and 72 h incubation, 
respectively); in contrast, no significant anti-proliferative effect was observed with the 
negative controls (Fig. 6b). These results suggest that the anti-cancer effects of the 
AuNPs are related to RelA gene silencing, and are not due to cell death or 
cytotoxicity. 
When the NF-κB transcription factor is activated, tumour cells are known to become 
resistant to conventional chemo- and radiotherapy [52]. Recently, a combination 
strategy has been applied to re-sensitise cancer cells to chemotherapeutics by 
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suppressing the NF-κB signalling pathway [53]. It has been reported that transfection 
of anti-RelA siRNA improved the sensitivity of PC-3 cells to chemotherapeutics 
(docetaxel and ciplatin) [54], due most likely to the downregulation of anti-apoptosis 
genes such as Bcl-2 and Bcl-xL (these are NF-κB downstream genes) [55]. In this 
study, when combined with Paclitaxel (PTX, an alkaloid with microtubule-targeting 
capacity, widely utilised to treat a variety of cancers [56]), the downregulation of 
NF-κB mediated by siRelA using Au110-PEI-PEG5000-AA achieved a synergistic 
anti-proliferative effect in comparison to either PTX or 
Au110-PEI-PEG5000-AA.siRNA alone (Fig. S8), indicating the therapeutic potential of 
this combination strategy in the treatment of prostate cancer.  
3.5. In vivo studies using AuNP.siRNA complexes 
3.5.1 Toxicity 
As described in section 3.2, Au-PEI-PEG and Au-PEI-PEG-AA did not cause 
significant cytotoxicity in vitro. The in vivo toxicity of AuNPs was further assessed 
using mice (n = 4 mice per group) (Fig. 7a, S9 and S10; Table S3). Two hours post 
intravenous administration of a single bolus? dose, AuNP.siRNA formulations 
(WR40, ~ 1 mg/kg siRNA) no increase in interferon alpha (IFN-α) levels were 
detected (Fig. S9). In addition, following treatment with either Paclitaxel (PTX, ~ 10 
mg/kg) alone, or Au110-PEI-PEG5000-AA.siRelA (WR40, ~ 1 mg/kg siRNA) alone, or 
a combination of AuNPs and PTX no significant decrease in body weight was 
detected over a 2 week period compared to the saline control group (Fig. 8a). At the 
endpoint (Day 14), the heart, liver, spleen, lung and kidneys were collected and 
analysed using H & E staining. No significant histological differences between 
samples from mice treated with PTX, AuNP.siRNA or the combination versus the 
saline control were detected (Fig. S10). In addition, the peripheral blood was analysed 
using the haemacytometer to further examine systemic toxicity (Table S3), the results 
indicate no significant stats? haematological toxicity following the test treatments. In 
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summary, these preliminary murine toxicology studies on the 
Au110-PEI-PEG5000-AA.siRNA formulation (WR40) indicate no significant signs of 
systemic toxicity.  
3.5.2 Pharmacokinetics 
The incorporation of PEG (PEGylation) into NPs is known to prevent aggregation and 
adsorption of blood components (i.e. serum proteins) [57] and therefore has become 
one of the most efficient approaches to improve the half-life of NPs in systemic 
circulation [58]. The circulation time of PEGylated NPs is influenced by the PEG Mw 
(proportional to the chain length), increases in circulation times of ~ 4, 7 and 17 min 
have been reported for micelles incorporating 5, 10, and 20 kDa of PEG, respectively 
[59]. For PEGylated liposomes, conflicting effects have been reported. In one study 
increased circulation was achieved when the PEG Mw was increased from 750 Da to 
5 kDa [60], in contrast another study found negligible effects with PEG Mw ranging 
from 350 Da to 2 kDa [61] suggesting that longer PEG lengths are required to prolong 
in vivo exposure.  
As described in Fig. 3c, AuNP formulations with longer PEGylation (Mw = 7500) 
demonstrated better in vitro stability compared to shorter PEGylation (Mw = 3500 and 
5000). However, longer PEGylation (Mw = 7500) negatively affected the siRNA 
binding efficiency in comparison to shorter PEGylation (Mw = 3500 and 5000) (Fig. 
S7). Under the experimental conditions used in this study, Au110-PEI-PEG5000-AA 
could efficiently complex siRNA achieving a formulation with favourable 
physicochemical properties, and consequently the pharmacokinetic profile of this 
construct was evaluated.  
The plasma concentrations versus time for siFAM alone (~ 1 mg/kg) and siFAM 
complexed with Au110-PEI-PEG5000 or Au110-PEI-PEG5000-AA (WR40) (n = 4 mice 
per group) are shown in Fig. 7b. Plasma concentrations of free siRNA decreased 
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rapidly, with only residual levels detected less than 15 min post administration. In 
contrast, the siRNAs complexed with PEGylated AuNPs were more slowly cleared 
from the plasma, over 60 min post administration (Fig. 7b).  
The pharmacokinetic parameters were generated by fitting to a one-compartmental 
model (Table 1). The rank order in systemic exposure (area under the curve, AUC) 
was Au110-PEI-PEG5000-AA ≈ Au110-PEI-PEG5000 > siFAM, where the AUC values 
calculated for AuNP.siRNA formulations were significantly (p < 0.05) higher than 
free siFAM. In addition, PEGylated formulations significantly (p < 0.05) reduced 
clearance (CL) values compared to free siFAM,  no significant difference was 
observed between targeted and non-targeted formulations (Table 1). Corresponding 
with a decrease in CL, a trend towards longer circulating time (i.e. the half-life, t1/2) 
was observed with a rank order of Au110-PEI-PEG5000-AA > Au110-PEI-PEG5000 > 
siFAM, where the t1/2 value of Au110-PEI-PEG5000-AA.siFAM (6.20 min) was 
significantly higher than those of Au110-PEI-PEG5000.siFAM (4.98 min, p < 0.05) and 
siFAM (0.46 min, p < 0.001). In summary, these results show that the 
Au110-PEI-PEG5000-AA.siRNA formulation achieved a 13.5 fold increase in systemic 
exposure of siRNA relative to the naked control.  
3.5.3 Tissue distribution 
It is known that the leaky blood vessels in solid tumours provide access to circulating 
NPs with particle size < 500 nm via the “enhanced penetration and retention” (EPR) 
effect [62]. However, NPs above 100 nm are generally recognised by the MPS (e.g. 
liver Kupffer cells) [63]. In addition, positively charged NPs, due to non-specific 
adsorption of serum proteins, may be entrapped in the lung [63]. It has been reported 
that the majority of drugs delivered by NPs was found inside the liver, lung and 
spleen [64] and in contrast, minimal drug distribution was observed in tumours [e.g. < 
5% of injection dose (ID)/g] [65] [66].  
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In this study, the tissue distribution of siRNA was analysed ex vivo 2 h after 
intravenous injection of a single dose containing siFAM alone (~ 1 mg/kg) or siFAM 
complexed with Au110-PEI-PEG5000 or Au110-PEI-PEG5000-AA (WR40) (n = 4 mice 
per group) (Fig. 7c). It is not surprising that free siRNA did not show efficient 
retention in excised tissues (< 7% ID/g). In contrast, the siRNA delivered by AuNP 
formulations was mainly found in the liver (~ 40% ID/g), tumour (~ 15% ID/g) and 
lung (~ 10% ID/g), thus the accumulation of siRNA in the tumour was greatly 
improved (Fig. 7c) in comparison with previous studies [65] [66]. Although not 
statistically different?, the tumour uptake of the targeted AuNP tended to be greater 
versus the untargeted NP implying that the addition of anisamide targeting ligand may 
further assist the tissue uptake [21].  
3.5.4 In vivo anti-tumour effects 
It is well known that the NF-κB signalling pathway plays a key role in development, 
maintenance, and progression of solid tumours and haematological malignancies [67] 
[68], therefore presenting a promising target for cancer therapy [52]. siRNA-based 
blockage of NF-κB has resulted in in vitro and in vivo anti-proliferative and 
anti-metastasis effects [69] [70] [71] [72]. In this study, the therapeutic efficacy of 
Au110-PEI-PEG5000-AA complex (WR40) containing anti-RelA siRNA (~ 1 mg/kg) in 
PC-3 xenograft mice was assessed following intravenous administration (n = 4 mice 
per group) (Fig. 7d). Results show that the Au110-PEI-PEG5000-AA complex 
containing siRelA significantly (p < 0.05) retarded tumour growth relative to 
Au110-PEI-PEG5000-AA complex containing negative control siRNA and the saline 
control group. This anti-tumour effect was mainly due to the RelA gene knockdown 
(Fig. S11).  
Recently, it has been reported that intraperitoneal injections of anti-RelA siRNA 
decreased the expression of NF-κB in gastric cancer, enhanced the sensitivity of 
tumour cells to PTX, and thereby achieved a synergistic therapeutic effect with PTX 
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in tumour bearing mice [73]. Since PTX is also the first line chemotherapeutic for 
prostate cancer, the rational for the combination of AuNP.siRNA formulation and 
PTX in prostate cancer therapy was assessed in this study (Fig. 7d). When a 
combination of the Au110-PEI-PEG5000-AA.siRelA complex and PTX was given to 
diseased mice, the anti-tumour efficacy was significantly (p < 0.01) higher than either 
of the individual monotherapies (Fig. 7d). This synergistic effect confirmed the 
hypothesis that the inactivation of NF-κB (Fig. S11) can enhance the sensitivity of 
tumour cells to PTX, which is most likely due to the downregulation of anti-apoptosis 
genes regulated by NF-κB [55] (Fig. 6a). In addition, the combination of the 
Au110-PEI-PEG5000-AA.siRelA complex and PTX did not induce any significant 
toxicity (Fig. 7a, S9, S10 and Table S3), indicating the potential for clinical 
translation of this combination strategy in the treatment of prostate carcinoma.   
 
4. Conclusions 
A range of positively charged anisamide-targeted PEGylated AuNPs (namely 
Au-PEI-PEG-AA) were developed for delivery of therapeutic siRNA in the treatment 
of prostate carcinoma. One of these Au-PEI-PEG-AA, namely Au110-PEI-PEG5000-AA 
could effectively complex siRNA via the electrostatic interaction, and the resultant 
complexation (Au110-PEI-PEG5000-AA.siRNA) demonstrated favourable particle size, 
surface charge, and stability. The in vitro studies show cell specific internalisation 
indicating the function of the anisamide targeting ligand. Following intravenous 
administration the tumour reduction was reflected in the siRNA-mediated knockdown 
of NF-κB. More importantly, a synergistic therapeutic effect was promoted by a 
corresponding downregulation of target gene in combination with chemotherapeutics, 
without showing significant toxicity. These results imply that the anisamide-targeted 
 28 
AuNP vector provides a promising strategy for combination therapy in the treatment 
of prostate cancer. 
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